The Market Fieldbook

Confirming your account

Your account is being prepared. You will be redirected securely in a moment.

The Market Fieldbook

Company Observatory

MEDP

Medpace Holdings, Inc.

Healthcare · Medical - Diagnostics & Research

Overall research band Strong
Quality Exceptional
Valuation Mixed
Balance sheet Exceptional
Market confirmation Exceptional

One-minute company read

What this report can tell you now

What the company does

Medpace Holdings, Inc. is a contract research organization (CRO) founded in Cincinnati, Ohio, in 1992, that provides clinical development and research services to pharmaceutical, biotechnology, and medical device companies across North America, Europe, and Asia. The company offers a comprehensive suite of services covering the entire product lifecycle, including the design of development programs, central laboratory coordination, project management, regulatory navigation, clinical trial oversight, data management and analytics, pharmacovigilance, new drug application support, and post-marketing clinical assistance. Medpace also delivers specialized bio-analytical laboratory testing, clinical human pharmacology studies, imaging services, and expert electrocardiography (ECG) reading for clinical research. Its revenue model is based on providing these research and development services to its clients.

The current research profile is Mixed Setup, with balance-sheet strength. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

  • Read the latest filing or company update.
  • Check the financial period behind each metric.
  • Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC171.7%Model input; read with the evidence status and period context.
Operating margin21.1%Model input; read with the evidence status and period context.
Revenue CAGR · 4 years22.0%Model input; read with the evidence status and period context.
FCF margin26.9%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.
Evidence detailSee exact inputs, source context, and model-aware metrics.
HistoryReview score and research changes over time.
MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.